

14 January 2020

Our Ref: RFI 32619

Dear

**Freedom of Information Act 2000
Information Requested in Relation to Breast Cancer and Urothelial Cancer
Patients**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to the above which you requested on 13 December 2019.

A response to each of the questions raised has been provided by the Hospital Services Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital (informationgovernance@setrust.hscni.net) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

Rebecca Kelly
Information Governance Assistant

Q1. Within your health trust how many patients are currently [within the past 3 months] being treated with the following for breast cancer ?

A1.

Abemaciclib + aromatase inhibitor *	0
Abemaciclib + Fulvestrant	0
Alpelisib + Fulvestrant	0
Atezolizumab	0
Bevacizumab	0
Eribulin	1
Everolimus + Exemestane	Unknown
Fulvestrant as a single agent	10
Gemcitabine + paclitaxel	0
Lapatinib	0
Neratinib	0
Olaparib	0
Palbociclib + aromatase inhibitor*	17
Pertuzumab + trastuzumab + docetaxel	3
Ribociclib + aromatase inhibitor*	0
Ribociclib + Fulvestrant	0
Talazoparib	0
Herceptin SC	35
Herceptin IV	8
Transtuzumab biosimilar SC	0
Transtuzumab biosimilar IV	0
Trastuzumab emtansine	2
Other active systemic anti-cancer therapy **	** 35 patients started on other active anti-cancer therapy during this time. *aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole **eg. docetaxel, vinorelbine or capecitabine as a single agent

Q2. How many patients are being treated for

Q2a. Neo-adjuvant breast cancer;

A2a.

Transtuzumab total SC	Total number included in previous question, unable to separate out
Transtuzumab total IV	Total number included in previous question, unable to separate out

Q2b. Adjuvant breast cancer;

A2b.

Transtuzumab total SC	Total number included in previous question, unable to separate out
Transtuzumab total IV	Total number included in previous question, unable to separate out

Q3. In the past 3 months, how many Urothelial cancer patients were treated with;

Atezolizumab

Carboplatinum in combination with another agent

Carboplatinum single agent

Cisplatinum in combination with another agent

Cisplatinum single agent

Nivolumab

Pembrolizumab

Any other chemo regimen without cisplatinum or carboplatinum

Other active systemic anti-cancer therapy [please state]

Palliative care only

A3. Urothelial cancer patients are not treated at the Ulster Hospital.